- The Myeloma Beacon - https://myelomabeacon.org -
AT9283
By: Admin; Published: November 10, 2010 @ 5:56 pm | Comments Disabled
| Brand Name: | |
| Generic Name: | |
| Code Name: | AT9283 |
| Company: | Astex |
| FDA Clinical Phase: | 2 |
Description:
AT9283 is a kinase inhibitor that prevents cell division, thereby stopping the growth of cancer cells. Several Phase 1 clinical trials have shown that AT9283 is safe in patients with blood and solid-tumor cancers, and pre-clinical studies have indicated that AT9283, alone or in combination with other myeloma treatments, is effective in multiple myeloma cells.
Clinical Trials:
For a list of clinical trials studying AT9283 for the treatment of multiple myeloma, see ClinicalTrials.gov [1].
Website for AT9283: http://www.astex-therapeutics.com/products/pipeline.php [2]
Article printed from The Myeloma Beacon: https://myelomabeacon.org
URL to article: https://myelomabeacon.org/resources/2010/11/10/at9283/
URLs in this post:
[1] ClinicalTrials.gov: http://www.clinicaltrials.gov/ct2/results?term=AT9283&cond=myeloma
[2] http://www.astex-therapeutics.com/products/pipeline.php: http://www.astex-therapeutics.com/products/pipeline.php
Click here to print.
Copyright © The Beacon Foundation for Health. All rights reserved.